The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...
Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback